nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroxyaluminium—VDAC3—seminal vesicle—testicular cancer	0.0429	0.104	CbGeAlD
Dihydroxyaluminium—VDAC1—seminal vesicle—testicular cancer	0.0408	0.0986	CbGeAlD
Dihydroxyaluminium—VDAC2—gonad—testicular cancer	0.0372	0.09	CbGeAlD
Dihydroxyaluminium—Venous thrombosis—Carboplatin—testicular cancer	0.0312	0.0532	CcSEcCtD
Dihydroxyaluminium—VDAC3—gonad—testicular cancer	0.031	0.0749	CbGeAlD
Dihydroxyaluminium—VDAC2—female gonad—testicular cancer	0.0303	0.0731	CbGeAlD
Dihydroxyaluminium—VDAC1—gonad—testicular cancer	0.0295	0.0713	CbGeAlD
Dihydroxyaluminium—Fluid overload—Carboplatin—testicular cancer	0.027	0.0461	CcSEcCtD
Dihydroxyaluminium—VDAC2—testis—testicular cancer	0.0268	0.0648	CbGeAlD
Dihydroxyaluminium—VDAC3—female gonad—testicular cancer	0.0252	0.0609	CbGeAlD
Dihydroxyaluminium—VDAC1—female gonad—testicular cancer	0.024	0.0579	CbGeAlD
Dihydroxyaluminium—VDAC3—testis—testicular cancer	0.0224	0.054	CbGeAlD
Dihydroxyaluminium—VDAC1—testis—testicular cancer	0.0213	0.0514	CbGeAlD
Dihydroxyaluminium—VDAC2—lymph node—testicular cancer	0.0195	0.047	CbGeAlD
Dihydroxyaluminium—Extravasation—Carboplatin—testicular cancer	0.0193	0.0329	CcSEcCtD
Dihydroxyaluminium—TNNC1—testis—testicular cancer	0.0182	0.044	CbGeAlD
Dihydroxyaluminium—VDAC3—lymph node—testicular cancer	0.0162	0.0392	CbGeAlD
Dihydroxyaluminium—Diuresis—Cisplatin—testicular cancer	0.0159	0.0271	CcSEcCtD
Dihydroxyaluminium—Haemolysis—Cisplatin—testicular cancer	0.0155	0.0265	CcSEcCtD
Dihydroxyaluminium—VDAC1—lymph node—testicular cancer	0.0154	0.0372	CbGeAlD
Dihydroxyaluminium—Blindness transient—Methotrexate—testicular cancer	0.0148	0.0253	CcSEcCtD
Dihydroxyaluminium—Salivation—Ifosfamide—testicular cancer	0.0148	0.0252	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Carboplatin—testicular cancer	0.0142	0.0242	CcSEcCtD
Dihydroxyaluminium—TNNC1—lymph node—testicular cancer	0.0132	0.0319	CbGeAlD
Dihydroxyaluminium—Acidosis—Ifosfamide—testicular cancer	0.0103	0.0176	CcSEcCtD
Dihydroxyaluminium—Venous thrombosis—Cisplatin—testicular cancer	0.00914	0.0156	CcSEcCtD
Dihydroxyaluminium—Extravasation—Vinblastine—testicular cancer	0.00909	0.0155	CcSEcCtD
Dihydroxyaluminium—Fluid overload—Cisplatin—testicular cancer	0.00793	0.0135	CcSEcCtD
Dihydroxyaluminium—Extravasation—Bleomycin—testicular cancer	0.00767	0.0131	CcSEcCtD
Dihydroxyaluminium—Extravasation—Dactinomycin—testicular cancer	0.00716	0.0122	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Vinblastine—testicular cancer	0.00668	0.0114	CcSEcCtD
Dihydroxyaluminium—Extravasation—Ifosfamide—testicular cancer	0.00656	0.0112	CcSEcCtD
Dihydroxyaluminium—Infection—Carboplatin—testicular cancer	0.00596	0.0102	CcSEcCtD
Dihydroxyaluminium—Extravasation—Cisplatin—testicular cancer	0.00565	0.00965	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Bleomycin—testicular cancer	0.00564	0.00962	CcSEcCtD
Dihydroxyaluminium—Salivary hypersecretion—Ifosfamide—testicular cancer	0.00556	0.00948	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Dactinomycin—testicular cancer	0.00526	0.00898	CcSEcCtD
Dihydroxyaluminium—Coma—Ifosfamide—testicular cancer	0.00523	0.00892	CcSEcCtD
Dihydroxyaluminium—Extravasation—Etoposide—testicular cancer	0.00518	0.00884	CcSEcCtD
Dihydroxyaluminium—Cardiovascular disorder—Etoposide—testicular cancer	0.00514	0.00877	CcSEcCtD
Dihydroxyaluminium—Pain—Carboplatin—testicular cancer	0.00513	0.00875	CcSEcCtD
Dihydroxyaluminium—Angina pectoris—Vinblastine—testicular cancer	0.00484	0.00827	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Ifosfamide—testicular cancer	0.00482	0.00823	CcSEcCtD
Dihydroxyaluminium—Thrombophlebitis—Ifosfamide—testicular cancer	0.0048	0.00819	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Carboplatin—testicular cancer	0.00474	0.00809	CcSEcCtD
Dihydroxyaluminium—Polyuria—Ifosfamide—testicular cancer	0.00473	0.00807	CcSEcCtD
Dihydroxyaluminium—Venous thrombosis—Epirubicin—testicular cancer	0.00469	0.00801	CcSEcCtD
Dihydroxyaluminium—Venous thrombosis—Doxorubicin—testicular cancer	0.00434	0.00741	CcSEcCtD
Dihydroxyaluminium—Encephalopathy—Methotrexate—testicular cancer	0.00422	0.00719	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Cisplatin—testicular cancer	0.00416	0.00709	CcSEcCtD
Dihydroxyaluminium—Polyuria—Cisplatin—testicular cancer	0.00408	0.00696	CcSEcCtD
Dihydroxyaluminium—Urinary retention—Ifosfamide—testicular cancer	0.00395	0.00674	CcSEcCtD
Dihydroxyaluminium—Lung disorder—Methotrexate—testicular cancer	0.00382	0.00652	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Etoposide—testicular cancer	0.00381	0.0065	CcSEcCtD
Dihydroxyaluminium—Hyponatraemia—Cisplatin—testicular cancer	0.0036	0.00613	CcSEcCtD
Dihydroxyaluminium—Lung disorder—Epirubicin—testicular cancer	0.00358	0.00611	CcSEcCtD
Dihydroxyaluminium—Angina pectoris—Ifosfamide—testicular cancer	0.0035	0.00597	CcSEcCtD
Dihydroxyaluminium—Dehydration—Cisplatin—testicular cancer	0.00333	0.00568	CcSEcCtD
Dihydroxyaluminium—Lung disorder—Doxorubicin—testicular cancer	0.00331	0.00565	CcSEcCtD
Dihydroxyaluminium—Convulsion—Chlorambucil—testicular cancer	0.00328	0.00559	CcSEcCtD
Dihydroxyaluminium—Vertigo—Vinblastine—testicular cancer	0.00311	0.00531	CcSEcCtD
Dihydroxyaluminium—Extravasation—Methotrexate—testicular cancer	0.0031	0.00529	CcSEcCtD
Dihydroxyaluminium—Infection—Chlorambucil—testicular cancer	0.00307	0.00523	CcSEcCtD
Dihydroxyaluminium—Chills—Bleomycin—testicular cancer	0.00302	0.00515	CcSEcCtD
Dihydroxyaluminium—Convulsion—Vinblastine—testicular cancer	0.003	0.00512	CcSEcCtD
Dihydroxyaluminium—Extravasation—Epirubicin—testicular cancer	0.0029	0.00495	CcSEcCtD
Dihydroxyaluminium—Cardiovascular disorder—Epirubicin—testicular cancer	0.00288	0.00492	CcSEcCtD
Dihydroxyaluminium—Chills—Dactinomycin—testicular cancer	0.00281	0.0048	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Ifosfamide—testicular cancer	0.00277	0.00472	CcSEcCtD
Dihydroxyaluminium—Extravasation—Doxorubicin—testicular cancer	0.00269	0.00458	CcSEcCtD
Dihydroxyaluminium—Cardiovascular disorder—Doxorubicin—testicular cancer	0.00267	0.00455	CcSEcCtD
Dihydroxyaluminium—Pain—Chlorambucil—testicular cancer	0.00264	0.0045	CcSEcCtD
Dihydroxyaluminium—Chills—Ifosfamide—testicular cancer	0.00258	0.0044	CcSEcCtD
Dihydroxyaluminium—Coma—Methotrexate—testicular cancer	0.00247	0.00422	CcSEcCtD
Dihydroxyaluminium—Salivary hypersecretion—Epirubicin—testicular cancer	0.00246	0.0042	CcSEcCtD
Dihydroxyaluminium—Urticaria—Chlorambucil—testicular cancer	0.00245	0.00418	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Chlorambucil—testicular cancer	0.00244	0.00416	CcSEcCtD
Dihydroxyaluminium—Pain—Vinblastine—testicular cancer	0.00242	0.00413	CcSEcCtD
Dihydroxyaluminium—Oedema—Bleomycin—testicular cancer	0.00239	0.00408	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Cisplatin—testicular cancer	0.00239	0.00407	CcSEcCtD
Dihydroxyaluminium—Infection—Bleomycin—testicular cancer	0.00237	0.00405	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Ifosfamide—testicular cancer	0.00236	0.00402	CcSEcCtD
Dihydroxyaluminium—Coma—Epirubicin—testicular cancer	0.00231	0.00395	CcSEcCtD
Dihydroxyaluminium—Salivary hypersecretion—Doxorubicin—testicular cancer	0.00228	0.00388	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Chlorambucil—testicular cancer	0.00227	0.00388	CcSEcCtD
Dihydroxyaluminium—Thrombophlebitis—Methotrexate—testicular cancer	0.00227	0.00387	CcSEcCtD
Dihydroxyaluminium—Vertigo—Ifosfamide—testicular cancer	0.00225	0.00383	CcSEcCtD
Dihydroxyaluminium—Polyuria—Methotrexate—testicular cancer	0.00224	0.00382	CcSEcCtD
Dihydroxyaluminium—Hypotension—Bleomycin—testicular cancer	0.00223	0.00381	CcSEcCtD
Dihydroxyaluminium—Oedema—Dactinomycin—testicular cancer	0.00223	0.0038	CcSEcCtD
Dihydroxyaluminium—Infection—Dactinomycin—testicular cancer	0.00221	0.00378	CcSEcCtD
Dihydroxyaluminium—Convulsion—Ifosfamide—testicular cancer	0.00217	0.0037	CcSEcCtD
Dihydroxyaluminium—Coma—Doxorubicin—testicular cancer	0.00214	0.00365	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Epirubicin—testicular cancer	0.00213	0.00364	CcSEcCtD
Dihydroxyaluminium—Thrombophlebitis—Epirubicin—testicular cancer	0.00212	0.00362	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Chlorambucil—testicular cancer	0.00211	0.0036	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Vinblastine—testicular cancer	0.00208	0.00355	CcSEcCtD
Dihydroxyaluminium—Visual disturbance—Methotrexate—testicular cancer	0.00207	0.00354	CcSEcCtD
Dihydroxyaluminium—Pain—Bleomycin—testicular cancer	0.00204	0.00348	CcSEcCtD
Dihydroxyaluminium—Oedema—Ifosfamide—testicular cancer	0.00204	0.00348	CcSEcCtD
Dihydroxyaluminium—Chills—Etoposide—testicular cancer	0.00204	0.00347	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Cisplatin—testicular cancer	0.00203	0.00347	CcSEcCtD
Dihydroxyaluminium—Infection—Ifosfamide—testicular cancer	0.00203	0.00346	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Doxorubicin—testicular cancer	0.00197	0.00337	CcSEcCtD
Dihydroxyaluminium—Thrombophlebitis—Doxorubicin—testicular cancer	0.00197	0.00335	CcSEcCtD
Dihydroxyaluminium—Vomiting—Chlorambucil—testicular cancer	0.00196	0.00335	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Vinblastine—testicular cancer	0.00194	0.0033	CcSEcCtD
Dihydroxyaluminium—Back pain—Etoposide—testicular cancer	0.00191	0.00326	CcSEcCtD
Dihydroxyaluminium—Hypotension—Ifosfamide—testicular cancer	0.00191	0.00325	CcSEcCtD
Dihydroxyaluminium—Pain—Dactinomycin—testicular cancer	0.0019	0.00325	CcSEcCtD
Dihydroxyaluminium—Urticaria—Bleomycin—testicular cancer	0.0019	0.00324	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Bleomycin—testicular cancer	0.00189	0.00322	CcSEcCtD
Dihydroxyaluminium—Dizziness—Vinblastine—testicular cancer	0.00187	0.00319	CcSEcCtD
Dihydroxyaluminium—Convulsion—Cisplatin—testicular cancer	0.00187	0.00319	CcSEcCtD
Dihydroxyaluminium—Hyponatraemia—Epirubicin—testicular cancer	0.00185	0.00315	CcSEcCtD
Dihydroxyaluminium—Nausea—Chlorambucil—testicular cancer	0.00183	0.00313	CcSEcCtD
Dihydroxyaluminium—Vomiting—Vinblastine—testicular cancer	0.0018	0.00307	CcSEcCtD
Dihydroxyaluminium—Vertigo—Etoposide—testicular cancer	0.00177	0.00303	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Dactinomycin—testicular cancer	0.00176	0.003	CcSEcCtD
Dihydroxyaluminium—Oedema—Cisplatin—testicular cancer	0.00176	0.003	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Bleomycin—testicular cancer	0.00176	0.003	CcSEcCtD
Dihydroxyaluminium—Infection—Cisplatin—testicular cancer	0.00175	0.00298	CcSEcCtD
Dihydroxyaluminium—Pain—Ifosfamide—testicular cancer	0.00175	0.00298	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Cisplatin—testicular cancer	0.00172	0.00293	CcSEcCtD
Dihydroxyaluminium—Convulsion—Etoposide—testicular cancer	0.00171	0.00292	CcSEcCtD
Dihydroxyaluminium—Dehydration—Epirubicin—testicular cancer	0.00171	0.00292	CcSEcCtD
Dihydroxyaluminium—Hyponatraemia—Doxorubicin—testicular cancer	0.00171	0.00291	CcSEcCtD
Dihydroxyaluminium—Nausea—Vinblastine—testicular cancer	0.00168	0.00287	CcSEcCtD
Dihydroxyaluminium—Hypotension—Cisplatin—testicular cancer	0.00164	0.00281	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Dactinomycin—testicular cancer	0.00164	0.0028	CcSEcCtD
Dihydroxyaluminium—Urticaria—Ifosfamide—testicular cancer	0.00162	0.00277	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Ifosfamide—testicular cancer	0.00161	0.00275	CcSEcCtD
Dihydroxyaluminium—Infection—Etoposide—testicular cancer	0.0016	0.00273	CcSEcCtD
Dihydroxyaluminium—Dehydration—Doxorubicin—testicular cancer	0.00158	0.0027	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Etoposide—testicular cancer	0.00157	0.00268	CcSEcCtD
Dihydroxyaluminium—Angina pectoris—Epirubicin—testicular cancer	0.00155	0.00264	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Dactinomycin—testicular cancer	0.00152	0.0026	CcSEcCtD
Dihydroxyaluminium—Vomiting—Bleomycin—testicular cancer	0.00152	0.00259	CcSEcCtD
Dihydroxyaluminium—Hypotension—Etoposide—testicular cancer	0.00151	0.00257	CcSEcCtD
Dihydroxyaluminium—Pain—Cisplatin—testicular cancer	0.0015	0.00257	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Ifosfamide—testicular cancer	0.0015	0.00257	CcSEcCtD
Dihydroxyaluminium—Angina pectoris—Doxorubicin—testicular cancer	0.00143	0.00244	CcSEcCtD
Dihydroxyaluminium—Nausea—Bleomycin—testicular cancer	0.00142	0.00242	CcSEcCtD
Dihydroxyaluminium—Vomiting—Dactinomycin—testicular cancer	0.00142	0.00242	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Ifosfamide—testicular cancer	0.0014	0.00238	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Cisplatin—testicular cancer	0.00139	0.00237	CcSEcCtD
Dihydroxyaluminium—Pain—Etoposide—testicular cancer	0.00138	0.00235	CcSEcCtD
Dihydroxyaluminium—Dizziness—Ifosfamide—testicular cancer	0.00135	0.0023	CcSEcCtD
Dihydroxyaluminium—Nausea—Dactinomycin—testicular cancer	0.00132	0.00226	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Methotrexate—testicular cancer	0.00131	0.00223	CcSEcCtD
Dihydroxyaluminium—Vomiting—Ifosfamide—testicular cancer	0.0013	0.00221	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Cisplatin—testicular cancer	0.0013	0.00221	CcSEcCtD
Dihydroxyaluminium—Urticaria—Etoposide—testicular cancer	0.00128	0.00219	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Epirubicin—testicular cancer	0.00128	0.00218	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Etoposide—testicular cancer	0.00127	0.00217	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Epirubicin—testicular cancer	0.00123	0.00209	CcSEcCtD
Dihydroxyaluminium—Chills—Methotrexate—testicular cancer	0.00122	0.00208	CcSEcCtD
Dihydroxyaluminium—Nausea—Ifosfamide—testicular cancer	0.00121	0.00207	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Cisplatin—testicular cancer	0.0012	0.00205	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Etoposide—testicular cancer	0.00119	0.00203	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Doxorubicin—testicular cancer	0.00118	0.00201	CcSEcCtD
Dihydroxyaluminium—Back pain—Methotrexate—testicular cancer	0.00114	0.00195	CcSEcCtD
Dihydroxyaluminium—Chills—Epirubicin—testicular cancer	0.00114	0.00195	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Doxorubicin—testicular cancer	0.00113	0.00194	CcSEcCtD
Dihydroxyaluminium—Vomiting—Cisplatin—testicular cancer	0.00112	0.00191	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Methotrexate—testicular cancer	0.00112	0.0019	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Etoposide—testicular cancer	0.0011	0.00188	CcSEcCtD
Dihydroxyaluminium—Back pain—Epirubicin—testicular cancer	0.00107	0.00183	CcSEcCtD
Dihydroxyaluminium—Dizziness—Etoposide—testicular cancer	0.00107	0.00182	CcSEcCtD
Dihydroxyaluminium—Vertigo—Methotrexate—testicular cancer	0.00106	0.00181	CcSEcCtD
Dihydroxyaluminium—Chills—Doxorubicin—testicular cancer	0.00106	0.0018	CcSEcCtD
Dihydroxyaluminium—Nausea—Cisplatin—testicular cancer	0.00105	0.00178	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Epirubicin—testicular cancer	0.00104	0.00178	CcSEcCtD
Dihydroxyaluminium—Convulsion—Methotrexate—testicular cancer	0.00103	0.00175	CcSEcCtD
Dihydroxyaluminium—Vomiting—Etoposide—testicular cancer	0.00103	0.00175	CcSEcCtD
Dihydroxyaluminium—Vertigo—Epirubicin—testicular cancer	0.000995	0.0017	CcSEcCtD
Dihydroxyaluminium—Back pain—Doxorubicin—testicular cancer	0.000991	0.00169	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Doxorubicin—testicular cancer	0.000966	0.00165	CcSEcCtD
Dihydroxyaluminium—Convulsion—Epirubicin—testicular cancer	0.000959	0.00164	CcSEcCtD
Dihydroxyaluminium—Infection—Methotrexate—testicular cancer	0.000959	0.00164	CcSEcCtD
Dihydroxyaluminium—Nausea—Etoposide—testicular cancer	0.000958	0.00163	CcSEcCtD
Dihydroxyaluminium—Vertigo—Doxorubicin—testicular cancer	0.000921	0.00157	CcSEcCtD
Dihydroxyaluminium—Oedema—Epirubicin—testicular cancer	0.000904	0.00154	CcSEcCtD
Dihydroxyaluminium—Hypotension—Methotrexate—testicular cancer	0.000902	0.00154	CcSEcCtD
Dihydroxyaluminium—Infection—Epirubicin—testicular cancer	0.000898	0.00153	CcSEcCtD
Dihydroxyaluminium—Convulsion—Doxorubicin—testicular cancer	0.000888	0.00151	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Epirubicin—testicular cancer	0.000882	0.0015	CcSEcCtD
Dihydroxyaluminium—Hypotension—Epirubicin—testicular cancer	0.000845	0.00144	CcSEcCtD
Dihydroxyaluminium—Oedema—Doxorubicin—testicular cancer	0.000836	0.00143	CcSEcCtD
Dihydroxyaluminium—Infection—Doxorubicin—testicular cancer	0.000831	0.00142	CcSEcCtD
Dihydroxyaluminium—Pain—Methotrexate—testicular cancer	0.000826	0.00141	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Doxorubicin—testicular cancer	0.000816	0.00139	CcSEcCtD
Dihydroxyaluminium—Hypotension—Doxorubicin—testicular cancer	0.000781	0.00133	CcSEcCtD
Dihydroxyaluminium—Pain—Epirubicin—testicular cancer	0.000773	0.00132	CcSEcCtD
Dihydroxyaluminium—Urticaria—Methotrexate—testicular cancer	0.000767	0.00131	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Methotrexate—testicular cancer	0.000763	0.0013	CcSEcCtD
Dihydroxyaluminium—Urticaria—Epirubicin—testicular cancer	0.000718	0.00122	CcSEcCtD
Dihydroxyaluminium—Pain—Doxorubicin—testicular cancer	0.000715	0.00122	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Epirubicin—testicular cancer	0.000714	0.00122	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Methotrexate—testicular cancer	0.000712	0.00121	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Epirubicin—testicular cancer	0.000666	0.00114	CcSEcCtD
Dihydroxyaluminium—Urticaria—Doxorubicin—testicular cancer	0.000664	0.00113	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Doxorubicin—testicular cancer	0.000661	0.00113	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Methotrexate—testicular cancer	0.000661	0.00113	CcSEcCtD
Dihydroxyaluminium—Dizziness—Methotrexate—testicular cancer	0.000639	0.00109	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Epirubicin—testicular cancer	0.000618	0.00106	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Doxorubicin—testicular cancer	0.000616	0.00105	CcSEcCtD
Dihydroxyaluminium—Vomiting—Methotrexate—testicular cancer	0.000614	0.00105	CcSEcCtD
Dihydroxyaluminium—Dizziness—Epirubicin—testicular cancer	0.000598	0.00102	CcSEcCtD
Dihydroxyaluminium—Vomiting—Epirubicin—testicular cancer	0.000575	0.00098	CcSEcCtD
Dihydroxyaluminium—Nausea—Methotrexate—testicular cancer	0.000574	0.000979	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Doxorubicin—testicular cancer	0.000572	0.000976	CcSEcCtD
Dihydroxyaluminium—Dizziness—Doxorubicin—testicular cancer	0.000553	0.000943	CcSEcCtD
Dihydroxyaluminium—Nausea—Epirubicin—testicular cancer	0.000537	0.000916	CcSEcCtD
Dihydroxyaluminium—Vomiting—Doxorubicin—testicular cancer	0.000532	0.000907	CcSEcCtD
Dihydroxyaluminium—Nausea—Doxorubicin—testicular cancer	0.000497	0.000847	CcSEcCtD
